This procedure marks the first international coronary procedure taking place as a result of the company’s distribution agreement with OrbusNeich.
Queen Elizabeth Hospital Department of Medicine the Division of Cardiology Cardiac Catheterization Laboratory Director Michael Kang-Yin Lee said: “Orbital Atherectomy is simple to use. It is a very controllable and predictable atherectomy device and is especially useful for diffuse and severely calcified coronary arteries, ensuring the angioplasty procedures can be completed with ease and good results. OAS also helps to fill the gap of the conventional devices when treating calcified coronary arteries.”
CSI chairman, president and CEO Scott Ward said: “We are thrilled to begin introducing our proven coronary atherectomy technology to physicians worldwide. As our international distribution partner, OrbusNeich, identifies new markets, we are prepared to provide best-in-class training to physicians committed to improving patient outcomes within this underserved patient population.”
OrbusNeich chairman emeritus and founder Teddy Chien said: “I was very pleased to have witnessed the first ever Coronary Orbital Atherectomy procedure performed in Hong Kong. CSI’s device supports our key business focus of providing solutions for all complex vascular interventions. We look forward to continuing global distribution of this clinically proven technology to our customers.”
In July this year, CSI announced that it had signed an exclusive international distribution agreement with OrbusNeich to sell its coronary and peripheral OAS outside of the United States and Japan.
In January this year, CSI announced that it was the exclusive US distributor for OrbusNeich balloon products. Ultimately, CSI will offer a full line of semi-compliant, non-compliant and specialty balloons for both coronary and peripheral vascular procedures. OrbusNeich PCI balloons include the Sapphire® II Pro, the first and only 1.0mm coronary balloon available in the United States.
Source: Company Press Release
